Insider Trades159 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Sell | IONS | Holly B. Kordasiewicz | EVP, Chief Development Officer | 362 | $84.30 | $9.0B | -37.30% | +35.87% | $30.5K | -1.61% | — | Trim |
| Jul 7, 2026 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 20,536 | $84.95 | $9.0B | -37.30% | +35.87% | $1.7M | -19.07% | — | Trim |
| Jun 26, 2026 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 3,069 | $80.00 | $9.0B | -37.30% | +35.87% | $245.5K | -4.76% | — | Trim |
| Jun 26, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 11,270 | $64.67 | $9.0B | -37.30% | +35.87% | $728.9K | +0.00% | — | Trim |
| Jun 26, 2026 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 52,000 | $70.97 | $9.0B | -37.30% | +35.87% | $3.7M | +0.00% | — | Trim |
| Jun 25, 2026 | Sell | IONS | Eric Swayze | EVP Research | 10,602 | $79.18 | $9.0B | -37.30% | +35.87% | $839.5K | -32.76% | — | Trim |
| Jun 24, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 171,274 | $63.21 | $9.0B | -37.30% | +35.87% | $10.8M | +0.00% | — | Trim |
| Jun 12, 2026 | Sell | IONS | Holly B. Kordasiewicz | EVP, Chief Development Officer | 121,692 | $63.69 | $9.0B | -37.30% | +35.87% | $7.8M | +0.00% | — | Trim |
| May 13, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 9,072 | $55.54 | $9.0B | -37.30% | +35.87% | $503.9K | +0.00% | — | Trim |
| Apr 28, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 1,626 | $71.79 | $9.0B | -37.30% | +35.87% | $116.7K | -3.49% | — | Trim |
| Apr 16, 2026 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 973 | $75.04 | $9.0B | -37.30% | +35.87% | $73.0K | -0.83% | — | Trim |
| Apr 16, 2026 | Sell | IONS | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 4,902 | $75.17 | $9.0B | -37.30% | +35.87% | $368.5K | -4.76% | — | Trim |
| Apr 16, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 5,619 | $74.56 | $9.0B | -37.30% | +35.87% | $419.0K | -5.59% | — | Trim |
| Apr 2, 2026 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 6,193 | $74.05 | $9.0B | -37.30% | +35.87% | $458.6K | -27.47% | — | Trim |
| Mar 19, 2026 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 5,812 | $70.97 | $9.0B | -37.30% | +35.87% | $412.5K | -8.34% | — | Trim |
| Mar 16, 2026 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 400,219 | $63.22 | $9.0B | -37.30% | +35.87% | $25.3M | -3.65% | — | Trim |
| Mar 10, 2026 | Sell | IONS | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 74,554 | $60.26 | $9.0B | -37.30% | +35.87% | $4.5M | +0.00% | — | Trim |
| Mar 9, 2026 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 10,148 | $75.25 | $9.0B | -37.30% | +35.87% | $763.7K | -14.02% | — | Trim |
| Mar 9, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 309,227 | $68.41 | $9.0B | -37.30% | +35.87% | $21.2M | -0.50% | — | Trim |
| Mar 3, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 8,797 | $71.19 | $9.0B | -37.30% | +35.87% | $626.3K | -4.70% | — | Trim |
| Mar 3, 2026 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 40,212 | $57.69 | $9.0B | -37.30% | +35.87% | $2.3M | +0.00% | — | Trim |
| Mar 3, 2026 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 150,178 | $68.18 | $9.0B | -37.30% | +35.87% | $10.2M | -3.56% | — | Trim |
| Feb 13, 2026 | Sell | IONS | Eric Swayze | EVP Research | 15,642 | $81.76 | $9.0B | -37.30% | +35.87% | $1.3M | -18.18% | — | Trim |
| Feb 6, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 29,430 | $85.79 | $9.0B | -37.30% | +35.87% | $2.5M | -10.37% | — | Trim |
| Feb 2, 2026 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 150,178 | $70.27 | $9.0B | -37.30% | +35.87% | $10.6M | -4.09% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 5,296 | $82.96 | $9.0B | -37.30% | +35.87% | $439.4K | -10.44% | — | Trim |
| Jan 30, 2026 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 5,885 | $82.95 | $9.0B | -37.30% | +35.87% | $488.1K | -5.54% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Eric Swayze | EVP Research | 6,179 | $82.93 | $9.0B | -37.30% | +35.87% | $512.4K | -11.46% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 6,179 | $83.03 | $9.0B | -37.30% | +35.87% | $513.0K | -8.53% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 6,179 | $83.45 | $9.0B | -37.30% | +35.87% | $515.6K | -8.14% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 6,179 | $83.53 | $9.0B | -37.30% | +35.87% | $516.2K | -7.91% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 6,988 | $83.24 | $9.0B | -37.30% | +35.87% | $581.7K | -5.00% | — | Trim |
| Jan 30, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 62,970 | $82.72 | $9.0B | -37.30% | +35.87% | $5.2M | -18.15% | — | Trim |
| Jan 22, 2026 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 3,977 | $81.34 | $9.0B | -37.30% | +35.87% | $323.5K | -15.00% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 1,823 | $75.96 | $9.0B | -37.30% | +35.87% | $138.5K | -1.40% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Holly B. Kordasiewicz | EVP, Chief Development Officer | 4,141 | $75.66 | $9.0B | -37.30% | +35.87% | $313.3K | -3.45% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 8,056 | $75.75 | $9.0B | -37.30% | +35.87% | $610.3K | -3.17% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 8,353 | $75.95 | $9.0B | -37.30% | +35.87% | $634.4K | -4.68% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 8,480 | $75.11 | $9.0B | -37.30% | +35.87% | $636.9K | -3.53% | — | Trim |
| Jan 16, 2026 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 8,977 | $75.15 | $9.0B | -37.30% | +35.87% | $674.6K | -3.78% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 9,191 | $75.84 | $9.0B | -37.30% | +35.87% | $697.0K | -3.62% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 9,302 | $75.59 | $9.0B | -37.30% | +35.87% | $703.1K | -3.68% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Eric Swayze | EVP Research | 9,933 | $75.34 | $9.0B | -37.30% | +35.87% | $748.4K | -4.29% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 12,922 | $75.22 | $9.0B | -37.30% | +35.87% | $972.0K | -3.36% | — | Trim |
| Jan 16, 2026 | Sell | IONS | Brett P Monia | Chief Executive Officer | 44,034 | $74.82 | $9.0B | -37.30% | +35.87% | $3.3M | -3.19% | — | Trim |
| Jan 7, 2026 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 88,398 | $68.17 | $9.0B | -37.30% | +35.87% | $6.0M | +0.00% | — | Trim |
| Jan 2, 2026 | Sell | IONS | Eric Swayze | EVP Research | 46,926 | $70.00 | $9.0B | -37.30% | +35.87% | $3.3M | +0.00% | — | Trim |
| Nov 25, 2025 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 33,554 | $67.34 | $9.0B | -37.30% | +35.87% | $2.3M | +0.00% | — | Trim |
| Nov 6, 2025 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 8,000 | $76.17 | $9.0B | -37.30% | +35.87% | $609.4K | -14.08% | — | Trim |
| Nov 5, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 69,278 | $67.37 | $9.0B | -37.30% | +35.87% | $4.7M | +0.00% | — | Trim |
| Nov 3, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 3,360 | $66.86 | $9.0B | -37.30% | +35.87% | $224.7K | +0.00% | — | Trim |
| Oct 31, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 161,858 | $67.98 | $9.0B | -37.30% | +35.87% | $11.0M | -2.57% | — | Trim |
| Oct 16, 2025 | Sell | IONS | Eric Swayze | EVP Research | 53 | $73.62 | $9.0B | -37.30% | +35.87% | $3.9K | -6.58% | — | Trim |
| Oct 15, 2025 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 13,263 | $61.95 | $9.0B | -37.30% | +35.87% | $821.7K | -1.08% | — | Trim |
| Oct 14, 2025 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 47,800 | $62.95 | $9.0B | -37.30% | +35.87% | $3.0M | +0.00% | — | Trim |
| Oct 6, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 437 | $69.26 | $9.0B | -37.30% | +35.87% | $30.3K | -0.24% | — | Trim |
| Oct 6, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 1,625 | $69.37 | $9.0B | -37.30% | +35.87% | $112.7K | -5.09% | — | Trim |
| Oct 6, 2025 | Sell | IONS | Eric Swayze | EVP Research | 6,849 | $69.02 | $9.0B | -37.30% | +35.87% | $472.7K | -18.36% | — | Trim |
| Oct 6, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 23,641 | $62.46 | $9.0B | -37.30% | +35.87% | $1.5M | -1.63% | — | Trim |
| Oct 2, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 30,000 | $49.91 | $9.0B | -37.30% | +35.87% | $1.5M | +0.00% | — | Trim |
| Oct 2, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 129,328 | $63.33 | $9.0B | -37.30% | +35.87% | $8.2M | +0.00% | — | Trim |
| Oct 1, 2025 | Sell | IONS | Eric Swayze | EVP Research | 54,228 | $59.96 | $9.0B | -37.30% | +35.87% | $3.3M | +0.00% | — | Trim |
| Sep 30, 2025 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 99,600 | $59.51 | $9.0B | -37.30% | +35.87% | $5.9M | +0.00% | — | Trim |
| Sep 30, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 115,800 | $59.51 | $9.0B | -37.30% | +35.87% | $6.9M | +0.00% | — | Trim |
| Sep 29, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 50,600 | $60.70 | $9.0B | -37.30% | +35.87% | $3.1M | +0.00% | — | Trim |
| Sep 12, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 3,400 | $60.68 | $9.0B | -37.30% | +35.87% | $206.3K | +0.00% | — | Trim |
| Sep 9, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 23,900 | $46.98 | $9.0B | -37.30% | +35.87% | $1.1M | +0.00% | — | Trim |
| Sep 9, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 42,000 | $62.62 | $9.0B | -37.30% | +35.87% | $2.6M | +0.00% | — | Trim |
| Sep 5, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 500 | $46.90 | $9.0B | -37.30% | +35.87% | $23.4K | +0.00% | — | Trim |
| Sep 5, 2025 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 6,000 | $59.60 | $9.0B | -37.30% | +35.87% | $357.6K | -6.77% | — | Trim |
| Sep 3, 2025 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 6,324 | $48.57 | $9.0B | -37.30% | +35.87% | $307.1K | +0.00% | — | Trim |
| Sep 3, 2025 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 39,316 | $57.29 | $9.0B | -37.30% | +35.87% | $2.3M | +0.00% | — | Trim |
| Sep 3, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 65,600 | $45.57 | $9.0B | -37.30% | +35.87% | $3.0M | +0.00% | — | Trim |
| Sep 3, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 407,628 | $52.32 | $9.0B | -37.30% | +35.87% | $21.3M | +0.00% | — | Trim |
| Sep 2, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 10,000 | $50.37 | $9.0B | -37.30% | +35.87% | $503.7K | -11.15% | — | Trim |
| Sep 2, 2025 | Sell | IONS | Eric Swayze | EVP Research | 11,130 | $49.67 | $9.0B | -37.30% | +35.87% | $552.9K | -12.81% | — | Trim |
| Sep 2, 2025 | Buy | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 98,600 | $56.90 | $9.0B | -37.30% | +35.87% | $5.6M | +5.28% | — | Trim |
| Sep 2, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 179,800 | $52.57 | $9.0B | -37.30% | +35.87% | $9.5M | +0.00% | — | Trim |
| Aug 18, 2025 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 20,000 | $38.29 | $9.0B | -37.30% | +35.87% | $765.8K | +0.00% | — | Trim |
| Aug 5, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 10,000 | $42.86 | $9.0B | -37.30% | +35.87% | $428.6K | -10.05% | — | Trim |
| Aug 4, 2025 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 9,549 | $42.80 | $9.0B | -37.30% | +35.87% | $408.7K | -15.64% | — | Trim |
| Jul 30, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 4,864 | $38.80 | $9.0B | -37.30% | +35.87% | $188.7K | +0.00% | — | Trim |
| Jul 11, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 1,160 | $41.74 | $9.0B | -37.30% | +35.87% | $48.4K | -0.64% | — | Trim |
| Apr 16, 2025 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 680 | $28.37 | $9.0B | -37.30% | +35.87% | $19.3K | -0.57% | — | Trim |
| Apr 16, 2025 | Sell | IONS | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 3,016 | $28.36 | $9.0B | -37.30% | +35.87% | $85.5K | -5.93% | — | Trim |
| Apr 16, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 3,928 | $28.40 | $9.0B | -37.30% | +35.87% | $111.6K | -3.84% | — | Trim |
| Mar 11, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 140 | $32.32 | $9.0B | -37.30% | +35.87% | $4.5K | -0.08% | — | Trim |
| Feb 20, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 1,207 | $32.35 | $9.0B | -37.30% | +35.87% | $39.0K | -2.10% | — | Trim |
| Feb 4, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 6,165 | $31.62 | $9.0B | -37.30% | +35.87% | $194.9K | -9.69% | — | Trim |
| Feb 4, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 38,843 | $31.65 | $9.0B | -37.30% | +35.87% | $1.2M | -17.69% | — | Trim |
| Jan 31, 2025 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 1,327 | $32.46 | $9.0B | -37.30% | +35.87% | $43.1K | -1.40% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Eric Swayze | EVP Research | 1,367 | $32.31 | $9.0B | -37.30% | +35.87% | $44.2K | -2.77% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 1,406 | $32.40 | $9.0B | -37.30% | +35.87% | $45.6K | -1.40% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 1,406 | $32.49 | $9.0B | -37.30% | +35.87% | $45.7K | -2.16% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 1,484 | $32.20 | $9.0B | -37.30% | +35.87% | $47.8K | -2.37% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 1,523 | $32.44 | $9.0B | -37.30% | +35.87% | $49.4K | -1.36% | — | Trim |
| Jan 31, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 13,242 | $32.45 | $9.0B | -37.30% | +35.87% | $429.7K | -5.69% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Shannon L. Devers | EVP, Chief Human Resources Ofc | 4,267 | $32.78 | $9.0B | -37.30% | +35.87% | $139.9K | -2.36% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 4,430 | $32.70 | $9.0B | -37.30% | +35.87% | $144.9K | -1.66% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 5,400 | $32.70 | $9.0B | -37.30% | +35.87% | $176.6K | -2.12% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 6,523 | $32.79 | $9.0B | -37.30% | +35.87% | $213.9K | -2.42% | — | Trim |
| Jan 16, 2025 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 6,752 | $32.90 | $9.0B | -37.30% | +35.87% | $222.1K | -2.64% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 7,072 | $32.86 | $9.0B | -37.30% | +35.87% | $232.4K | -2.29% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Eric Swayze | EVP Research | 7,176 | $32.84 | $9.0B | -37.30% | +35.87% | $235.7K | -2.77% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 7,360 | $32.83 | $9.0B | -37.30% | +35.87% | $241.6K | -2.68% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 8,870 | $32.81 | $9.0B | -37.30% | +35.87% | $291.0K | -2.24% | — | Trim |
| Jan 16, 2025 | Sell | IONS | Brett P Monia | Chief Executive Officer | 33,445 | $32.63 | $9.0B | -37.30% | +35.87% | $1.1M | -2.31% | — | Trim |
| Nov 12, 2024 | Sell | IONS | Eric Swayze | EVP Research | 1,194 | $37.92 | $9.0B | -37.30% | +35.87% | $45.3K | -3.42% | — | Trim |
| Nov 12, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 6,630 | $38.05 | $9.0B | -37.30% | +35.87% | $252.3K | -3.81% | — | Trim |
| Oct 16, 2024 | Sell | IONS | Eric Swayze | EVP Research | 53 | $38.31 | $9.0B | -37.30% | +35.87% | $2.0K | -8.33% | — | Trim |
| Aug 28, 2024 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 651 | $49.40 | $9.0B | -37.30% | +35.87% | $32.2K | -0.38% | — | Trim |
| Aug 5, 2024 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 2,430 | $48.00 | $9.0B | -37.30% | +35.87% | $116.6K | -2.76% | — | Trim |
| Apr 16, 2024 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 905 | $41.66 | $9.0B | -37.30% | +35.87% | $37.7K | -0.99% | — | Trim |
| Apr 16, 2024 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 4,006 | $41.60 | $9.0B | -37.30% | +35.87% | $166.6K | -5.22% | — | Trim |
| Feb 16, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 387 | $44.49 | $9.0B | -37.30% | +35.87% | $17.2K | -0.22% | — | Trim |
| Feb 2, 2024 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 1,853 | $49.52 | $9.0B | -37.30% | +35.87% | $91.8K | -2.29% | — | Trim |
| Feb 2, 2024 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 1,885 | $49.52 | $9.0B | -37.30% | +35.87% | $93.3K | -2.33% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Eric Swayze | EVP Research | 1,940 | $49.56 | $9.0B | -37.30% | +35.87% | $96.1K | -5.35% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 1,961 | $49.67 | $9.0B | -37.30% | +35.87% | $97.4K | -3.87% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 1,961 | $50.04 | $9.0B | -37.30% | +35.87% | $98.1K | -2.20% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 1,995 | $49.67 | $9.0B | -37.30% | +35.87% | $99.1K | -3.94% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 1,995 | $50.04 | $9.0B | -37.30% | +35.87% | $99.8K | -2.23% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2,071 | $49.59 | $9.0B | -37.30% | +35.87% | $102.7K | -3.99% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2,106 | $49.59 | $9.0B | -37.30% | +35.87% | $104.4K | -4.23% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 2,125 | $49.54 | $9.0B | -37.30% | +35.87% | $105.3K | -2.24% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Onaiza Cadoret-Manier | EVP, Chf GL Pdt Str & Oper Ofc | 2,125 | $49.60 | $9.0B | -37.30% | +35.87% | $105.4K | -5.60% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 2,162 | $49.54 | $9.0B | -37.30% | +35.87% | $107.1K | -2.28% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Onaiza Cadoret-Manier | EVP,Chf GL Pdt Str & Oper Ofc | 2,162 | $49.60 | $9.0B | -37.30% | +35.87% | $107.2K | -5.70% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 23,501 | $49.37 | $9.0B | -37.30% | +35.87% | $1.2M | -11.89% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 23,907 | $49.37 | $9.0B | -37.30% | +35.87% | $1.2M | -12.10% | — | Trim |
| Feb 2, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 23,907 | $49.37 | $9.0B | -37.30% | +35.87% | $1.2M | -12.10% | — | Trim |
| Jan 31, 2024 | Sell | IONS | Eric Swayze | EVP Research | 12,680 | $51.63 | $9.0B | -37.30% | +35.87% | $654.7K | -15.95% | — | Trim |
| Jan 25, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 2,285 | $51.75 | $9.0B | -37.30% | +35.87% | $118.2K | -1.48% | — | Trim |
| Jan 25, 2024 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 6,450 | $51.75 | $9.0B | -37.30% | +35.87% | $333.8K | -12.11% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Joseph Baroldi | EVP, Chief Business Officer | 2,024 | $50.42 | $9.0B | -37.30% | +35.87% | $102.0K | -2.31% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Brian Birchler | EVP, Corp and Development Ops | 4,497 | $50.42 | $9.0B | -37.30% | +35.87% | $226.7K | -4.72% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 5,482 | $50.42 | $9.0B | -37.30% | +35.87% | $276.4K | -5.56% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Onaiza Cadoret-Manier | EVP, Chf GL Pdt Str & Oper Ofc | 5,564 | $50.42 | $9.0B | -37.30% | +35.87% | $280.5K | -5.23% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Eric Swayze | EVP Research | 6,305 | $50.42 | $9.0B | -37.30% | +35.87% | $317.9K | -6.50% | — | Trim |
| Jan 17, 2024 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 6,745 | $50.42 | $9.0B | -37.30% | +35.87% | $340.1K | -6.27% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 7,338 | $50.42 | $9.0B | -37.30% | +35.87% | $370.0K | -5.26% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 7,744 | $50.42 | $9.0B | -37.30% | +35.87% | $390.4K | -7.14% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 8,683 | $50.42 | $9.0B | -37.30% | +35.87% | $437.8K | -5.37% | — | Trim |
| Jan 17, 2024 | Sell | IONS | Brett P Monia | Chief Executive Officer | 32,059 | $50.42 | $9.0B | -37.30% | +35.87% | $1.6M | -8.38% | — | Trim |
| Jan 12, 2024 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 16,000 | $43.05 | $9.0B | -37.30% | +35.87% | $688.8K | +0.00% | — | Trim |
| Dec 28, 2023 | Buy | IONS | Brian Birchler | EVP, Corp and Development Ops | 22,529 | $48.89 | $9.0B | -37.30% | +35.87% | $1.1M | +0.47% | — | Trim |
| Dec 28, 2023 | Sell | IONS | Eric Swayze | EVP Research | 54,200 | $48.76 | $9.0B | -37.30% | +35.87% | $2.6M | +0.00% | — | Trim |
| Dec 28, 2023 | Buy | IONS | Elizabeth L Hougen | EVP, Finance & CFO | 89,023 | $48.89 | $9.0B | -37.30% | +35.87% | $4.4M | +0.73% | — | Trim |
| Dec 26, 2023 | Sell | IONS | Patrick R. O'Neil | EVP CLO & General Counsel | 41,650 | $49.40 | $9.0B | -37.30% | +35.87% | $2.1M | +0.00% | — | Trim |
| Dec 26, 2023 | Sell | IONS | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 50,000 | $49.40 | $9.0B | -37.30% | +35.87% | $2.5M | +0.00% | — | Trim |
| Dec 20, 2023 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 21,224 | $48.42 | $9.0B | -37.30% | +35.87% | $1.0M | +0.00% | — | Trim |
| Dec 20, 2023 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 45,226 | $48.36 | $9.0B | -37.30% | +35.87% | $2.2M | +0.00% | — | Trim |
| Dec 20, 2023 | Sell | IONS | Brett P Monia | Chief Executive Officer | 48,000 | $48.36 | $9.0B | -37.30% | +35.87% | $2.3M | +0.00% | — | Trim |
| Dec 14, 2023 | Sell | IONS | Richard S Geary | EVP, Chief Development Officer | 21,226 | $48.46 | $9.0B | -37.30% | +35.87% | $1.0M | +0.00% | — | Trim |
| Dec 14, 2023 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 45,224 | $48.46 | $9.0B | -37.30% | +35.87% | $2.2M | +0.00% | — | Trim |
| Dec 14, 2023 | Sell | IONS | Brett P Monia | Chief Executive Officer | 48,000 | $48.46 | $9.0B | -37.30% | +35.87% | $2.3M | +0.00% | — | Trim |
| Oct 17, 2023 | Sell | IONS | Eric Swayze | EVP Research | 52 | $47.95 | $9.0B | -37.30% | +35.87% | $2.5K | -8.95% | — | Trim |
| Oct 12, 2023 | Sell | IONS | Brett P Monia | Chief Executive Officer | 3,770 | $46.00 | $9.0B | -37.30% | +35.87% | $173.4K | -3.09% | — | Trim |
| Sep 28, 2023 | Sell | IONS | C Frank Bennett | EVP, Chief Scientific Officer | 4,460 | $46.50 | $9.0B | -37.30% | +35.87% | $207.4K | -6.35% | — | Trim |